What Landos Biopharma does

Landos Biopharma was a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Blacksburg, Virginia, focused on developing orally administered therapeutics for autoimmune diseases, with a primary emphasis on inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis. The company's scientific platform centered on the NOD-like receptor (NLR) family of immunometabolic regulators, with its lead clinical asset NX-13 being a first-in-class oral NLRX1 agonist that operates through a dual mechanism combining anti-inflammatory activity with facilitation of epithelial repair. The company had previously advanced a second candidate, BT-11, an oral IBD therapeutic that progressed toward Phase 1 clinical testing before being superseded by NX-13 as the lead program.

The company's core technology targeted NLRX1, a regulatory receptor that modulates immunometabolism and inflammation. NX-13 was being evaluated in the NEXUS Phase 2 proof-of-concept study (NCT05785715), a randomized, multicenter, double-blind, placebo-controlled trial enrolling 80 patients with moderate-to-severe ulcerative colitis testing 250 mg and 750 mg immediate-release doses over a 12-week induction period with a long-term extension phase. The target patient population included approximately 1.6 million Americans and 4 million global IBD sufferers, representing what the company characterized as a $9.2 billion annual market opportunity growing at 25%.

Landos operated as a pre-commercial entity, generating no product revenue during its independent existence. The company was financed through a $10M Series A led by Perceptive Advisors in 2017 and a subsequent $60M financing in 2019 led by Perceptive Advisors and RTW Investments. It maintained a lean organization of 11-50 employees under scientific leadership including Chief Scientific Officer Raquel Hontecillas. On May 23, 2024, AbbVie completed its acquisition of Landos for $212 million ($20.42 per share plus contingent value rights up to $11.14 per share tied to a clinical milestone), bringing NX-13 into AbbVie's immunology pipeline alongside assets such as Rinvoq and Skyrizi. Following the acquisition, Landos ceased operating as an independent entity and its NASDAQ listing under ticker LABP was terminated.

Name

Landos Biopharma

Legal name

Landos Biopharma, Inc.

Website

https://landosbiopharma.com

Company type

Public

Founded year

2017

Operating status

Acquired

Headcount range

11–50 employees

Short description

Landos Biopharma was a clinical-stage biopharmaceutical company developing oral NLRX1 agonist therapeutics for inflammatory bowel disease, targeting Crohn's disease and ulcerative colitis patients. It was acquired by AbbVie in May 2024 for $212 million.

Ownership category

akta.pro rank

Product category

Inflammatory Bowel Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Inflammatory Bowel Disease (IBD) Care (HLAKAEAD)

Keywords

• Oral therapeutics
• Inflammatory bowel disease
• NLRX1 agonist
• Autoimmune disease treatment
• Small molecule drugs

Headquarters

HQ city

Blacksburg

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Landos Biopharma developed orally administered small molecule therapeutics for autoimmune diseases, with a primary focus on inflammatory bowel disease (IBD). Its lead investigational asset, NX-13, is a first-in-class oral NLRX1 agonist with a dual mechanism of action (anti-inflammatory and epithelial repair) currently in Phase 2 clinical development for ulcerative colitis. A second candidate, BT-11, was an oral IBD therapeutic that advanced toward Phase 1 clinical testing.

Product overview

Landos Biopharma was a biopharmaceutical company focused on developing orally active therapeutics for autoimmune diseases, primarily targeting inflammatory bowel disease (IBD). The company advanced two lead therapeutic candidates: NX-13 (a first-in-class oral NLRX1 agonist currently in Phase 2 for ulcerative colitis) and BT-11 (an oral IBD treatment that previously entered clinical development). The company was acquired by AbbVie in May 2024, bringing NX-13 into AbbVie's immunology pipeline with potential novel approaches to treating UC and Crohn's disease.

Differentiator

Problem solved

Functional benefit

Products and services

• NX-13 First-in-class oral NLRX1 agonist (member of the NOD-like receptor family) for the treatment of ulcerative colitis and Crohn's disease. NLRX1 regulates immunometabolism and inflammation, with a dual mechanism of action that is anti-inflammatory and facilitates epithelial repair. Currently in Phase 2 clinical development as part of AbbVie's pipeline following the 2024 acquisition.
• BT-11 Oral therapeutic candidate for inflammatory bowel disease (Crohn's disease and ulcerative colitis). Previously Landos' lead therapeutic candidate before NX-13, with planned Phase 1 clinical testing to evaluate safety and efficacy in IBD patients.

Quantifiable outcome

• Phase 2 proof-of-concept trial (NEXUS) evaluating 80 patients with moderate to severe UC with 12-week induction study

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• AbbViecoreStrategic or Co-development Partner · 23 May 2024AbbVie completed acquisition of Landos Biopharma on May 23, 2024. Landos' lead investigational asset NX-13 (first-in-class oral NLRX1 agonist) was added to AbbVie's pipeline with potential to offer novel approach to treatment of ulcerative colitis and Crohn's disease. Acquisition price was $20.42 per share plus up to $11.14 per share contingent value right.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• AbbVie: AbbVie acquired Landos and is itself the dominant IBD player with Skyrizi, Rinvoq, and Humira. It is the most directly comparable benchmark and the acquirer of the NX-13 program, with deep commercial infrastructure in ulcerative colitis and Crohn's disease.
• Roche: Roche has an active IBD pipeline and is a major immunology company that frequently scouts and acquires IBD assets. It represents a potential strategic alternative acquirer and a benchmark for IBD pipeline competition.
• Gilead Sciences: Gilead partnered with Galapagos on filgotinib and has broader JAK-inhibitor interests in IBD. It is a comparable large pharma with active UC franchise ambition and parallel oral IBD development programs.
• Takeda (Entyvio): Takeda markets Entyvio (vedolizumab), a leading biologic for UC and Crohn's disease. As a major IBD franchise holder with established commercial presence, Takeda represents incumbent competition Landos/NX-13 would have displaced or augmented.
• Johnson & Johnson (Stelara/Tremfya): J&J markets Stelara (ustekinumab) and Tremfya in IBD, with a major immunology franchise. J&J also partnered with Protagonist Therapeutics on PTG-100, making it a directly comparable pharma partner and competitor in IBD R&D.

Direct peers

• Pfizer: Pfizer acquired Arena Pharmaceuticals in 2022 for etrasimod, an oral S1P modulator approved for UC. Pfizer is now one of the leading oral IBD players and a direct competitor in the same prescription setting as NX-13.
• Protagonist Therapeutics: Protagonist Therapeutics developed PTG-100 (JNJ-77242113), an oral peptide for UC partnered with J&J. It is a clinical-stage biotech with a directly comparable oral IBD therapeutic profile and partnership trajectory to Landos.
• Bristol-Myers Squibb (Zeposia): BMS developed Zeposia (ozanimod), an oral S1P modulator approved for moderate-to-severe ulcerative colitis. It competes directly in the oral UC space where Landos's NX-13 would launch, with a similar patient population and prescriber base.
• Galapagos NV: Galapagos developed filgotinib (Jyseleca), a JAK inhibitor for UC, in partnership with Gilead. It is a clinical-stage IBD company comparable in size and strategic positioning to pre-acquisition Landos, with similar exit-or-development dynamics.
• Eli Lilly (Omvoh): Eli Lilly developed mirikizumab (Omvoh), an IL-23 antagonist approved for UC and Crohn's. It is a direct competitor for moderate-to-severe IBD patients and represents the kind of advanced pipeline competitor NX-13 will face at launch.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/LandosBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Landos Biopharma